We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASPX
76
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$3.08M 0.12%
120,000
+70,000
+140% +$1.49M
ALKS icon
77
PUT
Alkermes
ALKS
$7.56B
$3.06M 0.12%
+714
New +$32K
AAPL icon
78
CALL
Apple
AAPL
$4.83T
$3.02M 0.12%
+1,200
New +$29.5K
AAPL icon
79
PUT
Apple
AAPL
$4.83T
$3.02M 0.12%
+1,200
New +$29.5K
RPRX
80
DELISTED
Repros Therapeutics Inc.
RPRX
$2.93M 0.11%
295,621
+229,643
+348% +$3.4M
VIRX
81
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.91M 0.11%
19
+1
+6% +$1.45K
SGEN
82
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$2.87M 0.11%
772
+596
+339% +$23.4K
AVNR
83
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$2.84M 0.11%
2,382
+512
+27% +$3.5K
AMT icon
84
CALL
American Tower
AMT
$82.3B
$2.74M 0.11%
+293
New +$27.9K
NBIX icon
85
CALL
Neurocrine Biosciences
NBIX
$15.6B
$2.63M 0.1%
1,675
+348
+26% +$5.2K
SHPG
86
PUT
DELISTED
Shire pic
SHPG
$2.58M 0.1%
+183
New +$45.4K
ABUS icon
87
PUT
Arbutus Biopharma
ABUS
$1.01B
$2.56M 0.1%
+1,212
New +$19.8K
OXGN
88
DELISTED
OXIGENE INC COM
OXGN
$2.55M 0.1%
1,187,598
+75,800
+7% +$176K
ACHC icon
89
PUT
Acadia Healthcare
ACHC
$2.54B
$2.53M 0.1%
+1,022
New +$50K
AGN
90
CALL
DELISTED
Allergan Inc
AGN
$2.51M 0.1%
141
-857
-86% -$142K
VCEL icon
91
Vericel Corp
VCEL
$1.99B
$2.5M 0.1%
+876,173
New +$2.9M
ALBO
92
DELISTED
Albireo Pharma Inc
ALBO
$2.49M 0.1%
49,760
+41,740
+520% +$2.4M
GERN icon
93
CALL
Geron
GERN
$861M
$2.45M 0.09%
4,859
+996
+26% +$2.46K
WGBS
94
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$2.42M 0.09%
+111,320
New +$2.48M
IMNN icon
95
PUT
Imunon
IMNN
$8.08M
$2.42M 0.09%
3
– –
CNSY
96
Cerenome
CNSY
$16.5M
$2.36M 0.09%
1
– –
SRPT icon
97
Sarepta Therapeutics
SRPT
$2.15B
$2.25M 0.09%
106,663
-20,109
-16% -$454K
EXAS
98
PUT
DELISTED
Exact Sciences
EXAS
$2.24M 0.09%
+1,154
New +$21.2K
CASC
99
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.18M 0.08%
+189,349
New +$2.89M
INCY icon
100
CALL
Incyte
INCY
$24.4B
$2.11M 0.08%
431
– –
2 3
4
5 6

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.